Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Comprehensive List of Guidance Documents at the Food and Drug Administration We welcome general comments on this list and on agency guidance documents at any time.
View Prospective Grant of Exclusive License: Use of Leptin and Leptin Analogs for the Treatment of Lipodystrophy Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before August 27, 2010 will be considered.
View Prospective Grant of Exclusive License: The Development of Human Therapeutics for the Treatment of Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 3, 2010 will be considered.
View Government-Owned Inventions; Availability for Licensing 2008-09-05 (HHS Reference No. E-238-2008/2-PCT-01).
View Cancer Therapy Evaluation Program Intellectual Property Option to Collaborator Comments must be received by NIH on or before May 6, 2010.
View Prospective Grant of Exclusive License: Development of PANVAC and Tumor Associated Antigens as Cancer Vaccines Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 3, 2010 will be considered.
View Prospective Grant of Exclusive License: Treatment of Glaucoma by Administration of Adenosine A3 Antagonists Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 29, 2010 will be considered.
View Prospective Grant of Exclusive License: Purified Inactivated Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3′-UTR of Dengue Types 1,2,3, and 4 Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before March 10, 2010 will be considered.
View Prospective Grant of Exclusive License: Monoclonal Antibodies Against Smallpox/Orthopoxviruses Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before February 19, 2010 will be considered.
View Prospective Grant of Exclusive License: Development of V-ATPase Inhibitor Compounds for the Treatment of Human Cancers and Osteoclastic Bone Diseases Excluding Rheumatoid Arthritis and Other Osteo-Specific Auto-Immune Diseases Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 12, 2010 will be considered.
View Prospective Granting of an Exclusive License 12/27/2002.
View Prospective Grant of Exclusive License: Development of a Companion Diagnostic Kit To Detect Asparagine Synthetase Expression Levels as a Method To Screen for the Drug Efficacy in Treatments for Pancreatic Cancer, Ovarian Cancer, and Multiple Myeloma Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before January 4, 2010 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Development of Anti-Angiogenesis Cancer Therapeutics Targeting Adrenomedullin or Proadrenomedullin N-Terminal 20 Peptide (PAMP) Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 30, 2009 will be considered.
View Office of the Commissioner Reorganization; Statement of Organizations, Functions, and Delegations of Authority
View The National Biodefense Science Board (NBSB), a Federal Advisory Committee to the Secretary; Request for Public Comment The public is asked to submit comments by October 30, 2009, to the NBSB e-mail box (NBSB@hhs.gov) in order to be considered by the Working Group in preparing the final document.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Use of CD47 Antibodies, Antisense Oligonucleotides, and Small Molecules To Treat Disease Affecting the Vascular System Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 15, 2009 will be considered.
View Prospective Grant of Exclusive License: Pain Control by Selective Ablation of Pain-Sensing Neurons by Administration of Resiniferatoxin Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 31, 2009 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Use of N-Acetyl-Mannosamine and Derivatives Thereof to Treat Muscle Wasting Diseases and Kidney Diseases Related to Hyposialylation Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 3, 2009 will be considered.
View Prospective Grant of Exclusive License: The Manufacture, Use, Distribution of and Sale of Fused Azepinone Cyclin Dependent Kinase Inhibitors as Therapeutics Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 18, 2009 will be considered.
View Prospective Grant of Exclusive License: The Development of Thalidomide Analogs for the Treatment of Cancer Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 20, 2009 will be considered.
View Prospective Grant of Exclusive License: Development of Therapeutics for Use in Humans To Induce Tolerance for Transplantation and To Treat T cell Lymphoma and Leukemia, Autoimmune Diseases Such as Lupus, and Graft-Versus-Host Disease Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 6, 2009 will be considered.